Sermorelin is a research compound studied for its role in performance & hormone research. This page covers mechanism of action, published studies, preclinical protocols, and analytical specifications.
Store lyophilized at -20°C. Reconstituted: 4°C, use within 28 days.
Reconstitution
Add 2ml bacteriostatic water per vial. Inject slowly along vial wall, swirl gently.
Mechanism of Action
Sermorelin (GHRH 1-29 NH2) is a synthetic 29-amino acid peptide corresponding to the biologically active N-terminal fragment of endogenous growth hormone-releasing hormone (GHRH). It was the first GHRH analog developed as a clinical diagnostic tool for GH deficiency, receiving FDA approval in 1997 as Geref.
GHRH Receptor Activation: Sermorelin binds to the GHRH receptor (GHRH-R), a G-protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. Receptor activation stimulates adenylyl cyclase, increasing intracellular cAMP, which activates protein kinase A (PKA). PKA phosphorylates CREB transcription factors, driving GH gene transcription and stimulating GH granule release from somatotrophs.
Half-life and Pulsatility: Sermorelin has a short plasma half-life of approximately 10–20 minutes, similar to endogenous GHRH. This brevity means that sermorelin-stimulated GH release occurs in physiological-like pulses rather than producing sustained GH elevation. This distinguishes sermorelin from longer-acting GHRH analogs (particularly CJC-1295 with DAC) and makes it the preferred GHRH analog when physiological GH pulsatility is the research goal.
Pituitary Dependence: Like all GHRH analogs, sermorelin requires an intact, functional pituitary to produce GH. In hypopituitary models where somatotroph cells are absent or non-functional, sermorelin produces no GH response. This pituitary dependence is important in research distinguishing central (hypothalamic-pituitary) from peripheral GH axis dysfunction.
Somatostatin Interaction: Sermorelin’s GH-stimulating effect is modulated by somatostatin (SRIF), the endogenous GH inhibitory peptide. Research examining the balance between GHRH and somatostatin signalling uses sermorelin as the GHRH axis input. Combination with GHSR agonists (ipamorelin, GHRP-2) also suppresses somatostatin release, producing synergistically amplified GH pulses.
Research Applications
GH Deficiency Diagnosis Models: As an FDA-approved diagnostic agent, sermorelin has an established protocol as a GH stimulation test, making it the reference GHRH analog for clinical research methodology.
GHRH Receptor Biology: Sermorelin is used to study GHRH-R signalling, receptor density, and downstream cAMP/CREB pathway activation in pituitary cell models.
Pulsatile GH Research: Sermorelin’s short half-life produces physiological GH pulse profiles, making it the preferred GHRH analog for research where pulsatility pattern (rather than total GH elevation) is the primary variable of interest.
Comparison with CJC-1295: Head-to-head research comparing sermorelin (short half-life, pulsatile) vs CJC-1295 No DAC (30-min half-life, amplified pulses) vs CJC-1295 DAC (7-day half-life, sustained elevation) is an active area for understanding how GH pulse architecture affects downstream physiological responses.
Somatopause Research: Age-related decline in GHRH signalling is studied using sermorelin stimulation tests in aged animal models to quantify somatotroph responsiveness and residual GH secretory capacity.
Key Published Research
Primary publications relevant to Sermorelin research. Full citations available via PubMed. QSC does not endorse or make claims based on this research.
Walker et al. (1984)
“Stimulation of Growth Hormone Secretion by 1-29 hGRF-NH2 in Normal Man” — Journal of Clinical Endocrinology & Metabolism
Original characterisation of sermorelin’s GH-stimulating activity in humans, establishing the dose-response relationship and pulsatile release kinetics.
Vittone et al. (1997)
“Effects of Single Nightly Injections of Growth Hormone-Releasing Hormone (GHRH 1-29) in Healthy Elderly Men” — Metabolism
Clinical study examining sermorelin’s effects on GH/IGF-1 axis in elderly subjects, establishing the somatopause research methodology.
Corpas et al. (1993)
“Human Growth Hormone and Human Aging” — Endocrine Reviews
Reviews the rationale for GHRH stimulation approaches in aging research and documents the GH/IGF-1 axis decline with age.
Research Protocol Reference
Model / Context
Dose Range
Route
Protocol Notes
Rodent GHRH Stimulation
1–10 μg/kg
Intravenous or subcutaneous injection
Acute single-dose for GH pulse measurement; serial blood sampling at 15–60 min post-injection
Aged Rodent Somatopause Model
1–4 μg/kg/day
Subcutaneous injection
Chronic nightly dosing for 4–12 weeks; endpoints: GH pulse amplitude, IGF-1, body composition
In Vitro Pituitary Cell
0.1–100 nM
Added to somatotroph culture
cAMP, CREB phosphorylation, and GH secretion assays
Frequently Asked Questions
What is sermorelin?
Sermorelin is a synthetic 29-amino acid analog of endogenous GHRH (growth hormone-releasing hormone). It binds to GHRH receptors on pituitary somatotrophs to stimulate pulsatile GH release. It received FDA approval as Geref for GH deficiency diagnosis in children.
What is the difference between sermorelin and CJC-1295?
Both are GHRH analogs that activate the same receptor, but differ in half-life. Sermorelin has a ~10–20 minute half-life, producing short physiological GH pulses. CJC-1295 (No DAC) has ~30 minutes; CJC-1295 (with DAC) has ~7 days. Sermorelin is preferred when physiological pulsatility is the research goal; CJC-1295 with DAC when sustained GH elevation is needed.
Does sermorelin require an intact pituitary?
Yes. Sermorelin stimulates the pituitary to produce GH — it does not deliver GH directly. In pituitary-deficient models where somatotrophs are absent, sermorelin produces no GH response. This is why sermorelin is used as a diagnostic test for pituitary vs hypothalamic GH deficiency.
How should sermorelin be stored?
Lyophilized sermorelin at -20°C. After reconstitution with bacteriostatic water, store at 4°C and use within 28 days.
What purity is QSC sermorelin?
≥99% by HPLC and mass spectrometry. COA published on product page, verifiable via Janoshik.
Research Use Only: All products sold on qsc-usa.com are intended strictly for laboratory research purposes only. They are not approved for human consumption, veterinary use, or any other application. Researchers are responsible for understanding and complying with local regulations in their jurisdiction.
